Galimi Francesco's Form 4 filing
Adicet Bio, Inc. (ACET) · filed Apr 5, 2022
- Accession no.
- 0001209191-22-023285
- Filed
- Apr 5, 2022
- Trade date
- Apr 1-4, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 8 non-derivative transactions and 4 derivative transactions. Open-market sales total $327.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Galimi FrancescoCIK 0001823996 | Officer (SVP & Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 1, 2022 | Common Stock | MOption exerciseAcquired | +7,621 | $5.97 | +$45,497.37 | 67,538 | Direct | |
| Apr 1, 2022 | Common Stock | SSaleDisposed | −7,621 | $21.00 | −$160,041 | 59,917 | Direct | |
| Apr 4, 2022 | Common Stock | MOption exerciseAcquired | +6,036 | $13.27 | +$80,097.72 | 65,953 | Direct | |
| Apr 4, 2022 | Common Stock | SSaleDisposed | −6,036 | $21.00 | −$126,756 | 59,917 | Direct | |
| Apr 4, 2022 | Common Stock | MOption exerciseAcquired | +168 | $5.97 | +$1,002.96 | 60,085 | Direct | |
| Apr 4, 2022 | Common Stock | SSaleDisposed | −168 | $21.00 | −$3,528 | 59,917 | Direct | |
| Apr 4, 2022 | Common Stock | MOption exerciseAcquired | +1,775 | $16.82 | +$29,855.5 | 61,692 | Direct | |
| Apr 4, 2022 | Common Stock | SSaleDisposed | −1,775 | $21.00 | −$37,275 | 59,917 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 1, 2022 | Common Stock | MOption exerciseDisposed | −7,621 | –F3 | – | 113,820 | Direct | |
| Apr 4, 2022 | Common Stock | MOption exerciseDisposed | −6,036 | $0.00 | $0 | 73,964 | Direct | |
| Apr 4, 2022 | Common Stock | MOption exerciseDisposed | −168 | –F3 | – | 113,652 | Direct | |
| Apr 4, 2022 | Common Stock | MOption exerciseDisposed | −1,775 | $0.00 | $0 | 26,625 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.740 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc."
Referenced by the price of 2 transactions in Table II.